CARY, N.NephroGenex, a biotechnology firm focused on kidney disease treatments, has licensed a proposed diabetic nephropathy drug from BioStratum.
Neuphropathy is a disease of the kidney.
The drug, Pyridorin, has shown promise in two Phase II clinical trials.
NephroGenex also recently licensed from Vanderbilt University an agreement under which Pyridorin can be used as a treatment for acute renal failure.
NephroGenex: www.neprogenex.com
